Investigating the Clinical Consequences of Flutemetamol-PET-scanning
Status:
Terminated
Trial end date:
2019-12-10
Target enrollment:
Participant gender:
Summary
The study examines subjects where there might be an indication for Amyloid-PET according to
the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a
Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and
disease course will be studied over 6 months.